139 related articles for article (PubMed ID: 18192498)
1. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.
Peterson EC; Laurenzana EM; Atchley WT; Hendrickson HP; Owens SM
J Pharmacol Exp Ther; 2008 Apr; 325(1):124-33. PubMed ID: 18192498
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
3. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of a therapeutic anti-methamphetamine antibody fragment: oligomerization and binding of active metabolites.
Peterson EC; Celikel R; Gokulan K; Varughese KI
PLoS One; 2013; 8(12):e82690. PubMed ID: 24349338
[TBL] [Abstract][Full Text] [Related]
5. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
7. A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments.
Nanaware-Kharade N; Thakkar S; Gonzalez GA; Peterson EC
Sci Rep; 2015 Jul; 5():12060. PubMed ID: 26159352
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine.
Celikel R; Peterson EC; Owens SM; Varughese KI
Protein Sci; 2009 Nov; 18(11):2336-45. PubMed ID: 19760665
[TBL] [Abstract][Full Text] [Related]
9. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.
Reichard EE; Nanaware-Kharade N; Gonzalez GA; Thakkar S; Owens SM; Peterson EC
Pharm Res; 2016 Dec; 33(12):2954-2966. PubMed ID: 27620175
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats.
Byrnes-Blake KA; Laurenzana EM; Carroll FI; Abraham P; Gentry WB; Landes RD; Owens SM
Eur J Pharmacol; 2003 Feb; 461(2-3):119-28. PubMed ID: 12586207
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats.
Byrnes-Blake KA; Laurenzana EM; Landes RD; Gentry WB; Owens SM
Eur J Pharmacol; 2005 Oct; 521(1-3):86-94. PubMed ID: 16182279
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
[TBL] [Abstract][Full Text] [Related]
13. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration.
Rivière GJ; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2000 Mar; 292(3):1042-7. PubMed ID: 10688621
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic anti-methamphetamine antibody fragment-nanoparticle conjugates: synthesis and in vitro characterization.
Nanaware-Kharade N; Gonzalez GA; Lay JO; Hendrickson HP; Peterson EC
Bioconjug Chem; 2012 Sep; 23(9):1864-72. PubMed ID: 22873701
[TBL] [Abstract][Full Text] [Related]
15. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
16. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
[TBL] [Abstract][Full Text] [Related]
17. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.
Miller ML; Moreno AY; Aarde SM; Creehan KM; Vandewater SA; Vaillancourt BD; Wright MJ; Janda KD; Taffe MA
Biol Psychiatry; 2013 Apr; 73(8):721-8. PubMed ID: 23098894
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
20. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.
Proksch JW; Gentry WB; Owens SM
J Pharmacol Exp Ther; 2000 Mar; 292(3):831-7. PubMed ID: 10688594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
